Managing Irritable Bowel Syndrome

Anastasi, Joyce K.; Capili, Bernadette; Chang, Michelle

doi:10.1097/01.naj.0000431911.65473.35

Cited by 14 publications

(24 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tegaserod is a 5-HT type 4 receptor partial agonist. The drug was initially approved by the FDA in 2002 for the treatment of IBS-C in women.In clinical trials, it was shown to be superior to placebo in improving global IBS symptoms, but it was withdrawn from the market in 2007 because of an increased risk of cardiovascular events 61 . Prucalopride is a very highly selective 5-HT type 4 receptor agonist.…”

Section: Serotonin Receptor Agonists and Antagonistsmentioning

confidence: 99%

“…They're often the first line of defense before stimulant or other types of laxatives are used. There is also less risk of cramping or explosive diarrhoea that occurs with stimulant laxatives 61 . A stimulant laxative is recommended in patients that have neat, soft stools which are hard to pass.…”

Section: Laxativesmentioning

confidence: 99%

“…They work by causing relaxation of smooth muscle in the bowel. In clinical practice, mebeverine hydrochloride, hyoscyamine butylbromide and peppermint oil are commonly used 61 . These medications are best taken 20-30 min before meals, three times per day.…”

Section: Antispasmodicsmentioning

confidence: 99%

“…Alosetron is a selective serotonin antagonist that acts at the 5-hydroxytryptamine (5-HT) type 3 receptor 61 . Alosetron reduces the pain, discomfort, frequency and urgency of defecation.…”

Section: Serotonin Receptor Agonists and Antagonistsmentioning

confidence: 99%

See 3 more Smart Citations

Irritable bowel syndrome - from etiopathogenesis to therapy

Radovanović-Dinić¹,

Tešić-Rajković²,

Grgov³

et al. 2018

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a chronic and relapsing functional gastrointestinal disorder that affects 9-23% of the population across the world. Patients with IBS are often referred to gastroenterology, undergo various investigations, take various medicines, take time off work and have a poor quality of life. The pathophysiology of IBS is not yet completely understood and seems to be multifactorial. Many pathogenetic factors, in various combinations, and not all necessarily present in each patient, can play an important role. Discomfort or abdominal pain relieived by defacation, asociated with a change in stool form, is a typical clinical manifestation of IBS. Many factors, such as emotional stress and eating, may exacerbate the symptoms. A timely diagnosis of IBS is important so that treatment which will provide adequate symptomatic relief (diarrhoea, constipation, pain and boaring) can be introduced. The diagnosis of IBS is not confirmed by a specific test or structural abnormality. It is made using criteria based on clinical symptoms such as Rome criteria, unless the symptoms are thought to be atypical. Today the Rome Criteria IV is the current gold-standard for the diagnoses of IBS. Treatment of patients with IBS requires a multidisciplinary approach. Some patients respond well to non-pharmacological treatment, while others also require pharmacological treatment. This review will provide a summary of pathophysiology, diagnostic criteria and therapies for IBS.

show abstract

Section: Serotonin Receptor Agonists and Antagonistsmentioning

confidence: 99%

Section: Laxativesmentioning

confidence: 99%

Section: Antispasmodicsmentioning

confidence: 99%

“…Alosetron is a selective serotonin antagonist that acts at the 5-hydroxytryptamine (5-HT) type 3 receptor 61 . Alosetron reduces the pain, discomfort, frequency and urgency of defecation.…”

Section: Serotonin Receptor Agonists and Antagonistsmentioning

confidence: 99%

See 2 more Smart Citations

Irritable bowel syndrome - from etiopathogenesis to therapy

Radovanović-Dinić¹,

Tešić-Rajković²,

Grgov³

et al. 2018

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

show abstract

“…This condition is characterized by recurrent episodes of functional gastrointestinal symptoms not caused by anatomical abnormalities or inflammation. The pathophysiological mechanisms related to IBS are not clearly understood [4] and are thought to result from a combination of visceral hypersensitivity, changes in gut microbiota, and altered gastrointestinal motility [5]. …”

Section: Introductionmentioning

confidence: 99%

Beyond Irritable Bowel Syndrome: The Efficacy of the Low Fodmap Diet for Improving Symptoms in Inflammatory Bowel Diseases and Celiac Disease

Testa

Imperatore

Rispo

et al. 2018

Dig Dis

View full text Add to dashboard Cite

Background and Aim: To evaluate the usefulness of a low FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) diet on patients with irritable bowel syndrome (IBS), non-active inflammatory bowel diseases (IBD), and celiac disease (CD) on a gluten-free diet (GFD). Methods: Dietetic interventional prospective study. IBS, IBD, and CD subjects were evaluated to check if they fulfilled the Rome III criteria. Each subject was educated to follow a low FODMAP diet after being evaluated by filling out questionnaires that assessed the quality of life (QoL) and symptoms experienced (IBS-SSS and SF-36), and was reevaluated after 1 and 3 months. Results: One hundred twenty-seven subjects were enrolled: 56 with IBS, 30 with IBD, and 41 with CD. IBS-SSS showed that abdominal symptoms improved after 1 and 3 months of diet in all subjects, with significant difference among the 3 groups at T0 (average scores IBS: 293 ± 137, IBD: 206 ± 86, CD: 222 ± 65, p < 0.001), but no difference at T3 (IBS: 88 ± 54, IBD: 73 ± 45, CD: 77 ± 49, p = ns). By analyzing the SF-36 questionnaire, we did not observe any difference between the 3 groups, in terms of response to diet (p = ns), we observed a clinical improvement from T0 to T3 for most of the questionnaire’s domains. Conclusions: A low FODMAP diet could be a valid option to counter abdominal symptoms in patients with IBS, non-active IBD, or CD on a GFD, and thus, improve their QoL and social relations.

show abstract